Anika Therapeutics (ANIK +3%) says that it expects FY12 and Q4 to come in better than expections. Q4 revenue should come in around $22M - $23M, above the current consensus estimate of $20.6M. For FY12, it expects to equal or exceed its previously announced guidance of $0.74 net income per diluted share. Additionally it's appointed Sylvia Cheung as its new CFO, effective April 1, 2013. Cheung will replace Kevin Quinlan, who is leaving effective March 31, 2013.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs